WEBINARS AND EVENTS Quarterly Molecular Tumor Board: Review targeted therapies and management options for gynecologic cancer patients. Speakers: Howard McLeod PharmD, FASCO, FCCP, Center for Precision Medicine, Utah Tech University Christina Annunziata MD, PhD, Gynecological Medical Oncologist, Inova Health, SGE at the NCI Women’s Malignancies Branch Teresa Boitano MD, Gynecologic Oncology, University of Alabama, Birmingham Rachel Elsey PharmD, BCOP, Cancer Genomics Coordinator, Avera Cancer Institute Date: 07/22/2025 Duration: 1 hour CEU: No The second session of our quarterly Molecular Tumor Board, in partnership with Clarified Health, focused on gynecologic cancer, provided comprehensive insights from tumor genomic profiling and germline results. We discussed critical biomarker results necessary for an informed discussion guiding treatment decisions. State-of-the-art and evidence-based assessment of Myriad Oncology’s tests and results Summarized, and de-identified, patient cases focusing on germline and tumor genomic landscapes Discussion of hereditary implications of genomic findings Prioritization of targeted therapy options based on genomic findings Hear from our Speaker Howard McLeod PharmD, FASCO, FCCP, Center for Precision Medicine, Utah Tech University Christina Annunziata MD, PhD, Gynecological Medical Oncologist, Inova Health, SGE at the NCI Women’s Malignancies Branch Teresa Boitano MD, Gynecologic Oncology, University of Alabama, Birmingham Rachel Elsey PharmD, BCOP, Cancer Genomics Coordinator, Avera Cancer Institute